Effectiveness of an Adriamycin Immunoconjugate that Recognizes the C-erbB-2 Product on Breast Cancer Cell Lines

Hiromitsu Jinno, Masakazu Ueda, Kohji Enomoto, Tadashi Ikeda, Psarras Kyriakos, Masaki Kitajima

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Adriamycin (ADM) was chemically conjugated to a murine monoclonal antibody, A0011, which recognizes the c-erbB-2 product, via a disulfide bond using N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) and 2-iminothiolane (2-IT). The molar ratio of ADM to the monoclonal antibody ranged from 15:1 to 25:1 and enzyme-linked immunosorbent assay (ELISA) showed that the binding activity of the conjugate was almost retained. We compared the efficacy of A0011 alone, ADM alone, the A0011-ADM conjugate, and a non-specific murine IgM-ADM conjugate, against the human breast cancer cell lines SK-BR-3, MDA-MB-361, MCF-7, and BT-20. The A0011-ADM conjugate was observed to be ten times more cytotoxic to the cell lines overexpressing the c-erbB-2 product, namely, SK-BR-3 and MDA-MB-361, than free ADM, but it showed weak cytotoxicity against the cell lines with a low level of c-erbB-2 product expression, namely, MCF-7 and BT-20. However, free A0011 and nonspecific murine IgM-ADM conjugate showed no cytotoxicity toward any of the four cell lines, while the addition of a tenfold molar excess of A0011 inhibited conjugate cytotoxicity. These data suggest that conjugate cytotoxicity is antibody-mediated. Moreover, conjugate cytotoxicity at 10-6M was correlated with antigen volume, and the data were fitted to the regression equation y = -11.63 logX + 116.38 where the correlation coefficient = 0.950. Our results indicate that targeting therapy aiming at the c-erbB-2 product may be useful in the treatment of breast cancers overexpressing the c-erbE-2 product.

Original languageEnglish
Pages (from-to)501-507
Number of pages7
JournalSurgery today
Issue number7
Publication statusPublished - 1996
Externally publishedYes


  • Adriamycin
  • Breast cancer
  • Immunoconjugate
  • Targeting therapy
  • c-erbB-2

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Effectiveness of an Adriamycin Immunoconjugate that Recognizes the C-erbB-2 Product on Breast Cancer Cell Lines'. Together they form a unique fingerprint.

Cite this